Related Experiment Video
Updated: Mar 22, 2026
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Targeted Radionuclide Therapy of Melanoma
Abdullah Norain1, Ekaterina Dadachova1
1Department of Radiology, Albert Einstein College of Medicine, Bronx, NY.
Abstract:
An estimated 60,000 individuals in the United States and 132,000 worldwide are yearly diagnosed with melanoma. Until recently, treatment options for patients with stages III-IV metastatic disease were limited and offered marginal, if any, improvement in overall survival. The situation changed with the introduction of B-RAF inhibitors and anti-cytotoxic T-lymphocyte antigen 4 and anti-programmed cell death protein 1 immunotherapies into the clinical practice. With only some patients responding well to the immune therapies and with very serious side effects and high costs of immunotherapy, there is still room for other approaches for the treatment of metastatic melanoma. Targeted radionuclide therapy of melanoma could be divided into the domains of radioimmunotherapy (RIT), radiolabeled peptides, and radiolabeled small molecules. RIT of melanoma is currently experiencing a renaissance with the clinical trials of alpha-emitter (213)Bi-labeled and beta-emitter (188)Rhenium-labeled monoclonal antibodies in patients with metastatic melanoma producing encouraging results. The investigation of the mechanism of efficacy of melanoma RIT points at killing of melanoma stem cells by RIT and involvement of immune system such as complement-dependent cytotoxicity. The domain of radiolabeled peptides for targeted melanoma therapy has been preclinical so far, with work concentrated on radiolabeled peptide analogues of melanocyte-stimulating hormone receptor and on melanin-binding peptides. The field of radiolabeled small molecule produced radioiodinated benzamides that cross the cellular membrane and bind to the intracellular melanin. The recent clinical trial demonstrated measurable antitumor effects and no acute or midterm toxicities. We are hopeful that the targeted radionuclide therapy of metastatic melanoma would become a clinical reality as a stand-alone therapy or in combination with the immunotherapies such as anti-PD1 programmed cell death protein 1 monoclonal antibodies within the next few years.
Insights
Targeted radionuclide therapy offers a promising new avenue for treating metastatic melanoma, potentially improving outcomes for patients unresponsive to immunotherapy. This approach includes radioimmunotherapy, radiolabeled peptides, and small molecules, showing encouraging early results.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunology
Background:
- Melanoma, particularly stages III-IV metastatic disease, has limited treatment options with marginal survival benefits.
- Recent advances include BRAF inhibitors and immunotherapies (anti-CTLA-4, anti-PD-1), but challenges like patient response, side effects, and cost remain.
- Targeted radionuclide therapy presents an alternative or complementary strategy for metastatic melanoma.
Purpose of the Study:
- To review the current landscape and potential of targeted radionuclide therapy for metastatic melanoma.
- To explore different modalities within radionuclide therapy: radioimmunotherapy, radiolabeled peptides, and small molecules.
- To discuss the mechanisms of action and clinical prospects of these therapies.
Main Methods:
- Review of clinical trials and preclinical research in targeted radionuclide therapy for melanoma.
- Analysis of radioimmunotherapy (RIT) using alpha- and beta-emitters like Bismuth-213 and Rhenium-188.
- Examination of radiolabeled peptides targeting melanocyte-stimulating hormone receptors and melanin-binding peptides.
- Evaluation of radiolabeled small molecules, such as radioiodinated benzamides, that target intracellular melanin.
Main Results:
- Radioimmunotherapy (RIT) with alpha-emitter (213)Bi and beta-emitter (188)Re labeled antibodies shows encouraging results in metastatic melanoma patients.
- RIT's efficacy may involve targeting melanoma stem cells and engaging the immune system via mechanisms like complement-dependent cytotoxicity.
- Preclinical studies of radiolabeled peptides show promise, while a recent clinical trial of radiolabeled small molecules demonstrated antitumor effects without significant toxicity.
Conclusions:
- Targeted radionuclide therapy, encompassing RIT, peptides, and small molecules, is a developing field for metastatic melanoma.
- Encouraging results from RIT and small molecule trials suggest potential clinical utility.
- Radionuclide therapy may serve as a standalone treatment or in combination with immunotherapies like anti-PD-1 antibodies in the near future.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies